1. Home
  2. FTEK vs ITRM Comparison

FTEK vs ITRM Comparison

Compare FTEK & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FTEK
  • ITRM
  • Stock Information
  • Founded
  • FTEK 1987
  • ITRM 2015
  • Country
  • FTEK United States
  • ITRM Ireland
  • Employees
  • FTEK N/A
  • ITRM N/A
  • Industry
  • FTEK Pollution Control Equipment
  • ITRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • FTEK Industrials
  • ITRM Health Care
  • Exchange
  • FTEK Nasdaq
  • ITRM Nasdaq
  • Market Cap
  • FTEK N/A
  • ITRM 35.6M
  • IPO Year
  • FTEK N/A
  • ITRM 2018
  • Fundamental
  • Price
  • FTEK $0.96
  • ITRM $1.02
  • Analyst Decision
  • FTEK Strong Buy
  • ITRM Strong Buy
  • Analyst Count
  • FTEK 1
  • ITRM 2
  • Target Price
  • FTEK $4.00
  • ITRM $7.00
  • AVG Volume (30 Days)
  • FTEK 17.8K
  • ITRM 536.8K
  • Earning Date
  • FTEK 05-12-2025
  • ITRM 05-13-2025
  • Dividend Yield
  • FTEK N/A
  • ITRM N/A
  • EPS Growth
  • FTEK N/A
  • ITRM N/A
  • EPS
  • FTEK N/A
  • ITRM N/A
  • Revenue
  • FTEK $25,133,000.00
  • ITRM N/A
  • Revenue This Year
  • FTEK $22.06
  • ITRM N/A
  • Revenue Next Year
  • FTEK $10.39
  • ITRM $108.39
  • P/E Ratio
  • FTEK N/A
  • ITRM N/A
  • Revenue Growth
  • FTEK N/A
  • ITRM N/A
  • 52 Week Low
  • FTEK $0.87
  • ITRM $0.81
  • 52 Week High
  • FTEK $1.34
  • ITRM $3.02
  • Technical
  • Relative Strength Index (RSI)
  • FTEK 50.47
  • ITRM 44.07
  • Support Level
  • FTEK $0.94
  • ITRM $0.88
  • Resistance Level
  • FTEK $0.98
  • ITRM $1.14
  • Average True Range (ATR)
  • FTEK 0.02
  • ITRM 0.10
  • MACD
  • FTEK -0.00
  • ITRM -0.01
  • Stochastic Oscillator
  • FTEK 50.00
  • ITRM 30.56

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: